Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group LY.16/LYSARC Relevance (RV-FOL-GELARC-0683) study - A Phase III Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab plus Lenalidomide (CC-5013) versus Rituximab plus Chemotherapy Followed by Rituximab in Subjects with Previously Untreated Follicular Lymphoma - was closed to accrual on November 10th, 2014.

Forty-six Canadian patients were randomized to the study within a year. The target accrual was reached approximately 5 months earlier than expected due to the study's rapid accrual worldwide.

We thank all participating centres, staff and patients for their contributions to this study.